BRCA2

And if anybody thinks there's genetics with CFCs...

Okay, BRCA, you're talking, everyone's gonna say, "What about the BRCA, the BRCA1 and BRCA2?" That's questionable.

I'm telling you, that's questionable, and I, I can go into that.

Let me just real briefly say this to you.

So anyway, so I was talking about the BRCA gene and all that stuff.

So the BRCA gene...

Now, a BRCA gene, there's BRCA1 and BRCA2.

You would get, whether you're a man or a woman, has, we always think of it with breast CFCs, but it's not only that.

Welcome to BRCA and Beyond, a hereditary cancer podcast where we face genetics, fear, and the future together.

I'm Marissa Stahelski, a BRCA2 previvor, colon cancer survivor, wife, mom, and your host.

If you're navigating hereditary cancer, facing difficult medical decisions, recovering from surgery, or learning what it means to live with inherited cancer risk, You're in the right place.

Each week, we dig into what this journey really looks like through my own reflections and through honest conversations with patients, advocates, researchers, and medical experts.

As all of us know, somebody who carries a genetic mutation with different lifetime risks and different cancers, right? Like our story is not ending tomorrow.

Our story will continue to follow us for the rest of my life.

And I don't know what's to come with the future of my children that also have a 50%, you know, chance of inheriting the mutation, BRCA2, that I carry.

So for me, I have to be very careful and protect that space and make sure that that's a challenge somebody's willing to take on with me and walk through every step.

Yeah.

Dr. Backus, anything to add in regards to the role of PARP inhibitors? What if you had a patient with a BRCA2 mutation?

I think those are definitely a group that you would consider.

But those were barely any in the trials.

In the Ruby 2, they couldn't do the forest plots because there weren't enough patients with HRR mutations or with BRCA2.

So we see it works.

But looking at your data, Dr. Paludik, what you were just showing in a DMMR study, in Ruby in the part two, like now your hazard ratio goes from 0.3 to 0.6. Like that's puzzling me a little bit.

Yeah.

Dr. Backus, anything to add in regards to the role of PARP inhibitors? What if you had a patient with a BRCA2 mutation?

I think those are definitely a group that you would consider.

But those were barely any in the trials.

In the Ruby 2, they couldn't do the forest plots because there weren't enough patients with HRR mutations or with BRCA2.

So we see it works.

But looking at your data, Dr. Paludik, what you were just showing in a DMMR study, in Ruby in the part two, like now your hazard ratio goes from 0.3 to 0.6. Like that's puzzling me a little bit.

Like I know my mother just went through uterine cancer and got a hysterectomy.

So that was the first time that we were exposed to information about this BRCA2 gene

and this

testing so that we could maybe approach her healthcare differently going forward now also.

Welcome to BRCA and Beyond, a hereditary cancer podcast where we face genetics, fear, and the future together.

I'm Marissa Stahelski, a BRCA2 previvor, colon cancer survivor, wife, mom, and your host.

If you're navigating hereditary cancer, facing difficult medical decisions, recovering from surgery, or learning what it means to live with inherited cancer risk, You're in the right place.

Each week, we dig into what this journey really looks like through my own reflections and through honest conversations with patients, advocates, researchers, and medical experts.

After reading the biopsy report, Bridget says she realized that she was screwed.

She had stage two intraductal carcinoma with the BRCA2 mutation.

Her cancer uses estrogen and progesterone to grow, so she had a bilateral mastectomy and was put on hormone suppression, which put her into menopause until she could have a hysterectomy and oophorectomy in 2019.

It took a while to process and adjust to menopause, the medications, the side effects, her new body, the way she felt, and the emotional impact of all that she had gone through, including the dissolution of her engagement.